Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) has shared an announcement.
Telix Pharmaceuticals Limited announced the cessation of certain securities, specifically 67,000 share rights and 436,190 share appreciation rights, due to the lapse of conditional rights that were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s operational and financial strategies.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of diagnostic and therapeutic products, particularly in the field of oncology. The company is known for its innovative approach to cancer treatment and diagnostics, leveraging advanced technologies to enhance patient outcomes.
Average Trading Volume: 1,384,665
Technical Sentiment Signal: Buy
Current Market Cap: A$8.14B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.